Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012)
Vertex Pharmaceuticals (VRTX) recorded quarterly Finished Goods of $23.3 million in Q3 2012, down 0.81% quarter-over-quarter from $23.5 million in Q2 2012, and up 94.18% on a YoY basis from $12.0 million in Q4 2011.
Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012) Analysis & Trends
Vertex Pharmaceuticals' Finished Goods history runs 2 years deep, the most recent figure standing at $23.3 million for Q3 2012.
- In Q3 2012, Finished Goods rose 94.18% year-over-year to $23.3 million; the TTM figure through Sep 2012 stood at $23.3 million (up 94.18% YoY), while the FY2011 annual figure was $33.2 million, changed N/A from the prior year.
- Finished Goods was $23.3 million for Q3 2012 at Vertex Pharmaceuticals, down from $23.5 million in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $33.2 million in Q4 2011 to a low of $12.0 million in Q3 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 23.32 Mn |
| Jun 30, 2012 | 23.51 Mn |
| Mar 31, 2012 | 26.35 Mn |
| Dec 31, 2011 | 33.21 Mn |
| Sep 30, 2011 | 12.01 Mn |